STLN (Starling Oncology) YoY EBITDA Growth: 59.03% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLN Starling Oncology Inc STLN
60 GF Score
Price $6.99
GF Value $2.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Starling Oncology YoY EBITDA Growth?

Starling Oncology STLN +4.98% 60 YoY EBITDA Growth is 59.03% as of Jun. 2026. GuruFocus rates STLN with a GF Score™ of 60/100 and a GF Value™ of $2.80 (Significantly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Starling Oncology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 59.03%.

Starling Oncology's EBITDA per Share for the three months ended in Jun. 2026 was $-0.06.

Starling Oncology YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Starling Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology YoY EBITDA Growth Chart

Starling Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 37.17 186.67 -1,018.27 29.01 32.15

Starling Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.86 19.02 71.32 106.29 59.03
STLN
60GF Score
Starling Oncology Inc STLN
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Starling Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.46--0.678)/ | -0.678 |
=32.15 %

Starling Oncology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.059--0.144)/ | -0.144 |
=59.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 59.03% mean?
Starling Oncology (STLN) has a YoY EBITDA Growth of 59.03% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Starling Oncology and its competitors.
Is Starling Oncology's YoY EBITDA Growth too high?
Starling Oncology's current YoY EBITDA Growth is 59.03%. Overall, Starling Oncology has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's YoY EBITDA Growth compare to GMRS and SRTA?
Starling Oncology's YoY EBITDA Growth of 59.03% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Starling Oncology and its competitors. Starling Oncology's current YoY EBITDA Growth is 59.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.80, compared to a current price of $6.99 — trading 149.5% above its estimated fair value. The current YoY EBITDA Growth is 59.03%. Starling Oncology's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Starling Oncology (STLN), the current YoY EBITDA Growth is 59.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starling Oncology (STLN) Overvalued in 2026?

Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued. The current stock price of $6.99 is trading 149.5% above its estimated GF Value™ of $2.80. GuruFocus considers Starling Oncology to be Significantly Overvalued.

Key valuation signals for STLN:

  • YoY EBITDA Growth: 59.03%
  • GF Value™: $2.80 vs. price of $6.99 (149.5% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starling Oncology Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
60GF Score

Get the complete analysis for STLN

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price
$2.80
GF Value